| Identification | Back Directory | [Name]
LFM-A13 | [CAS]
244240-24-2 | [Synonyms]
LFM-A13(Z)
2-cyano-N-(2,5-dibromophenyl)
-3-oxobutanamide
(Z)-2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide
(2Z)-2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide
a-Cyano-b-hydroxy-b-methyl-N-(2,5-dibromophenyl)propenamide
α-cyano-β-hydroxy-β-methyl-n-(2,5-dibromophenyl)propenamide
2-Butenamide,2-cyano-N-(2,5-dibromophenyl)-3-hydroxy-, (2Z)-
(Z)-2-cyano-N-(2,5-dibroMophenyl)-3-hydroxybut-2-enaMide(LFM-A13) | [Molecular Formula]
Br2C11H8N2O2 | [MDL Number]
MFCD02179204 | [MOL File]
244240-24-2.mol | [Molecular Weight]
360 |
| Chemical Properties | Back Directory | [storage temp. ]
−20°C
| [solubility ]
DMSO: 15 mg/mL
| [form ]
powder
| [color ]
white
| [Stability:]
Stable for 2 years from date of purchase as supplied. PROTECT FROM MOISTURE. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
| Hazard Information | Back Directory | [Description]
LFM-A13 (244240-24-2) is a selective inhibitor of Bruton’s tyrosine kinase (BTK) – IC50‘s = 2.5 μM (recombinant BTK) and 17.2 μM (human BTK).1,2 It has also been shown to inhibit Polo-like kinase (PLK) – IC50 = 61 μM for human PLK3.3 LFM-A13 displayed no activity (concentrations up to 278 μM) at JAK1, JAK3, HCK, EGFRK and IRK2 or CDK1-3, CHK1, IKK, MAPK1, SAPK2a and ten other tyrosine kinases.3 | [Uses]
LFM-A13 is a potent inhibitor of Polo-like kinase (PLK), used for anti-breast cancer activity. Also a specific Bruton’s tyrosine kinase inhibitor. | [in vitro]
lfm-a13 inhibited recombinant btk expressed in a baculovirus expression vector system. besides its remarkable potency in btk kinase assays, lfm-a13 was also found to be a highly specific inhibitor of btk. even at very high concentrations, lfm-a13 did not affect the activity of other protein tyrosine kinases [1]. | [in vivo]
lfm-a13 exhibited a favorable pharmacokinetic behavior which was not adversely affected by the standard chemotherapy drugs and significantly improved the chemotherapy response and survival outcome of bcl-1 leukemia cells challenged mice. while only 14% of mice treated with the standard triple-drug combination treatment became long-term survivors, 41% of mice treated with this combination plus lfm-a13 survived long-term [2]. | [IC 50]
17.2 μm | [References]
1) Vassilev et al. (1999), Bruton’s tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex; J. Biol. Chem., 274 1646
2) Mahajan et al. (1999), Rational design and synthesis of a novel-anti-leukemic agent targeting Bruton’s tyrosine kinase (BTK), LFM-A13 [α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl)propenamide]; J. Biol. Chem. 274 9587
3) Uckun et al. (2007) Anti-breast cancer activity of LFM-A13, a potent inhibitor of polo-like kinase (PLK); Bioorg. Med. Chem. 15 800 |
|
|